23
Feb
2010
Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - CF, X - Pancreas, XX - MA
Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.
05
Feb
2010
Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Biomarker, X - Device (Diagnostic), XX - MA
On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.
Note: [...]
28
Jan
2010
Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis
Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.
Note: 2009 Year-in-Review Trend Analysis Coming [...]